Clinical Trial Update: Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/Phase 3 clinical trial evaluating Lucentis (ranibizumab) for age-related macular degeneration with pigment epithelial detachments.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Neovascular Age-related Macular Degeneration
• Pigment Epithelial Detachment
• Wet Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Pacific Eye Associates | Conditions: Age-related Macular Degeneration, Pigment Epithelial Detachment | Phase 2, Phase 3 | Status: COMPLETED